InvestorsHub Logo
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Re: trading.jeff post# 36377

Saturday, 10/22/2016 11:56:55 AM

Saturday, October 22, 2016 11:56:55 AM

Post# of 48316
This is on the agenda of the Nov 17 Analyst call:
"Special presentation and announcement regarding the Company's new device(s) including new research data."
It is very much possible that a new EP/IL-12 combo trial could use this device. Lung cancer (NSCLC) would be a great start for this device, IMO. It's the most prevalent and lethal of all cancers.